Compulsorylicensingtopatentedmedicines is favaborablefor developingcountries toprovide theirpatients withpatentedmedicines at lowprice. For thepatentees，they areobviously aginst compul-sorylicensingandmay avoidnottoinvest inthecountries whichadopt compulsorylicensing. Thearticle elaborates legislations andpractices insomecountries basedonTRIPs andanalyzes theimpactof compul-sorylicensingtopatentedmedicines toFDI.